BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pisaturo M, Russo A, Onorato L, Coppola N. Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis. Acta Biomed 2019;90:187-96. [PMID: 31124995 DOI: 10.23750/abm.v90i2.8374] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
Number Citing Articles
1 Wilton J, Wong S, Yu A, Ramji A, Cook D, Butt ZA, Alvarez M, Binka M, Darvishian M, Jeong D, Bartlett SR, Pearce ME, Adu PA, Yoshida EM, Krajden M, Janjua NZ. Real-world Effectiveness of Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort Study. Open Forum Infect Dis. 2020;7:ofaa055. [PMID: 32154326 DOI: 10.1093/ofid/ofaa055] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
2 Mushtaq S, Akhter TS, Khan A, Sohail A, Khan A, Manzoor S. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan. Front Pharmacol 2020;11:550205. [PMID: 32982753 DOI: 10.3389/fphar.2020.550205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Piekarska A, Berkan-Kawińska A, Deroń Z, Ciupińska J, Białkowska J. Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients - short report. Clin Exp Hepatol 2020;6:60-2. [PMID: 32166126 DOI: 10.5114/ceh.2020.93059] [Reference Citation Analysis]
4 Ahmed R, Kareem R, Venkatesan N, Botleroo RA, Ogeyingbo OD, Bhandari R, Gyawali M, Elshaikh AO. Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection. Cureus 2021;13:e17237. [PMID: 34540464 DOI: 10.7759/cureus.17237] [Reference Citation Analysis]